Targovax ASA (Targovax or the Company; OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard to treat solid tumors, announces the appointment of Dr. Torbjørn Furuseth as CFO, effective 24 September 2018. Dr. Erik Digman Wiklund, currently Targovaxs CFO, will become Chief Business Officer, replacing Michael Bogenstaetter
Carl Bjartmar appointed as CMO for Ascelia Pharma
AppointmentsAscelia Pharma announced on Friday Spetember 14 that Carl Bjartmar, MD, PhD, has been appointed as new Chief Medical Officer (CMO) for Ascelia Pharma. Carl has most recently worked as CMO for Wilson Therapeutics.
Sanofi preparing label extension for dupilumab
Latest NewsPositive Phase 3 results with Sanofi/Regeneron‘s IL4/IL-13-targeting antibody dupilumab (Dupixent) in adolescents with moderate-to-severe atopic dermatitis will form the basis of a regulatory submission in this new patient population, according to announcements of Sanofi.
Torbjørn Furuseth joins Targovax as CFO
AppointmentsTargovax ASA (Targovax or the Company; OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard to treat solid tumors, announces the appointment of Dr. Torbjørn Furuseth as CFO, effective 24 September 2018. Dr. Erik Digman Wiklund, currently Targovaxs CFO, will become Chief Business Officer, replacing Michael Bogenstaetter
Calcium does not contribute to heart failure
Latest NewsSlowing the leak of Calcium leak into cardiomyocytes does not improve the pumping malfunction in heart failure, German cardiologists report in Science Translational Medicine.
Boehringer Ingelheim bags ViraT in €210m deal
Latest NewsEMBL Ventures has announced that its portfolio company ViraTherapeutics is set to be acquired by Boehringer Ingelheim in a €210m million (US$245m) transaction.
Johanna Ivaska joins Orion Corporation
AppointmentsJohanna Ivaska, Academy Professor of Biochemistry has been appointed Head & Vice President of Oncology Research in Orion Corporation as of 1 October 2018. Ivaska joins Orion from the University of Turku and will continue working also there with her internationally recognised research team.
EU approves Shire’s van Willebrand factor
Latest NewsOrphan drug leader Shire plc has been granted EU marketing authorization for its recombinant van Willebrand factor (rVWF) vonicog alfa as second-line treatment for van Willebrand disease, the most common blot clotting disorder..
F-star Appoints Nessan Bermingham as Chairman
AppointmentsF-star, a biopharmaceutical company developing novel bispecific antibodies, today announces the appointment of Nessan Bermingham, Ph.D. as Chairman of its Board of Directors. Nessan succeeds John Edwards who has been F-stars Chairman for seven years and will remain as a non-executive director.
Crescendo Biologics appoints new CMO
AppointmentsCrescendo Biologics Ltd (Crescendo), today announced that Pavel Pisa, MD, PhD, has been appointed as Chief Medical Officer of the Company with immediate effect.
PD1/PD-L1blockers trigger metastases
Latest NewsDrug Developers dealing with PD1-PDL1 checkpoint inhibitors must consider new safety problems associated with the hyped cancer meds.